X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN LTD AJANTA PHARMA/
LUPIN LTD
 
P/E (TTM) x 18.2 147.1 12.4% View Chart
P/BV x 4.2 2.7 152.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 AJANTA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
LUPIN LTD
Mar-17
AJANTA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,750 103.9%   
Low Rs1,1061,384 79.9%   
Sales per share (Unadj.) Rs239.5387.4 61.8%  
Earnings per share (Unadj.) Rs52.856.6 93.2%  
Cash flow per share (Unadj.) Rs59.576.8 77.4%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0298.9 76.9%  
Shares outstanding (eoy) m88.77451.58 19.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.14.0 151.0%   
Avg P/E ratio x27.727.7 100.1%  
P/CF ratio (eoy) x24.620.4 120.5%  
Price / Book Value ratio x6.45.2 121.3%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m129,782707,513 18.3%   
No. of employees `0006.816.8 40.5%   
Total wages/salary Rs m3,76528,495 13.2%   
Avg. sales/employee Rs Th3,128.410,418.3 30.0%   
Avg. wages/employee Rs Th554.01,697.0 32.6%   
Avg. net profit/employee Rs Th689.71,523.0 45.3%   
INCOME DATA
Net Sales Rs m21,258174,943 12.2%  
Other income Rs m2421,065 22.7%   
Total revenues Rs m21,499176,008 12.2%   
Gross profit Rs m6,58444,931 14.7%  
Depreciation Rs m5969,122 6.5%   
Interest Rs m41,525 0.3%   
Profit before tax Rs m6,22635,349 17.6%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5399,785 15.7%   
Profit after tax Rs m4,68625,575 18.3%  
Gross profit margin %31.025.7 120.6%  
Effective tax rate %24.727.7 89.3%   
Net profit margin %22.014.6 150.8%  
BALANCE SHEET DATA
Current assets Rs m12,236119,542 10.2%   
Current liabilities Rs m3,46161,206 5.7%   
Net working cap to sales %41.333.3 123.8%  
Current ratio x3.52.0 181.0%  
Inventory Days Days6076 79.2%  
Debtors Days Days8490 94.0%  
Net fixed assets Rs m11,140131,660 8.5%   
Share capital Rs m177903 19.6%   
"Free" reserves Rs m20,237134,073 15.1%   
Net worth Rs m20,414134,976 15.1%   
Long term debt Rs m1056,478 0.0%   
Total assets Rs m24,486266,073 9.2%  
Interest coverage x1,519.424.2 6,285.1%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.90.7 132.0%   
Return on assets %19.210.2 188.1%  
Return on equity %23.018.9 121.2%  
Return on capital %30.519.3 158.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66781,885 14.2%   
Fx outflow Rs m1,61621,506 7.5%   
Net fx Rs m10,05260,378 16.6%   
CASH FLOW
From Operations Rs m2,85441,148 6.9%  
From Investments Rs m-2,604-25,287 10.3%  
From Financial Activity Rs m-24,332 -0.0%  
Net Cashflow Rs m24820,193 1.2%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TTK HEALTHCARE  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 218 Points Lower; Tata Steel & Tata Motors Top Losers(Closing)

Indian share markets ended lower in the final hour of the trade. At the closing bell, the BSE Sensex finished lower by 218 points and the NSE Nifty finished down by 82 points.

Related Views on News

SUN PHARMA plunges by 5%; BSE HEALTHCARE Index Down 3.4%

Jul 16, 2018 | Updated on Jul 16, 2018

SUN PHARMA share price has plunged by 5% and its Current Market Price is Rs 562. The BSE HEALTHCARE is down by 3.39%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 2.07%) and JUBILANT LIFE SCIENCES (up 1.80%). The top losers are SUN PHARMA (down 5.10%) and AJANTA PHARMA (down 5.30%).

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)

Jul 3, 2018

Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jul 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS